CMPS May Be 45% Below Fair Value as VA Trial and VA Trial Collaboration Sharpen the Path to Approval

Compass is now being judged on execution, not on whether psilocybin can work

This is a catalyst story, not a concept story. The setup has shifted from "could this work?" to "how much of the approval story is still missing?" At a $1.88B market cap, the stock still looks priced for a long line of execution risks. That leaves room for upside if the remaining milestones land on schedule, even if the market has not yet fully normalized those odds. In biotech, proof usually arrives in steps.

The de-risking chain is getting shorter

A few things changed recently. The FDA accepted the IND for COMP360 in PTSD, clearing the path for initiation of a late-stage trial. Compass is also working with the VA on a multi-site randomized controlled clinical trial in treatment-resistant depression, including veterans with concurrent PTSD. Meanwhile, final submission expected to be completed in Q4 keeps the near-term clock ticking.

That does not remove risk. But it does change the story from a single binary science bet to a sequence of de-risking steps: regulatory acceptance, broader trial data, a credible VA-backed study, and an NDA still due this year. When several of those links arrive close together, sentiment can rotate faster than the market expects.

COMP360 Phase 3 data address speed, magnitude, and durability

The data already reduce one common skepticism around psychedelic programs. Compass says its two Phase 3 trials are highly statistically significant. In COMP006, COMP360 25 mg versus 1 mg showed a mean difference of -3.8 on MADRS (p<0.001). The company also reports rapid onset from the day after administration, maintained through Week 6, with durability through at least Week 26 in responders after one or two doses. That combination matters because it speaks to three concerns at once: effect size, speed, and persistence.

Why that can change the commercial case

Trial success does not automatically become commercial value, but it helps if it reduces adoption friction. In TRD, clinicians and payers are more likely to pay attention when improvement starts quickly rather than waiting weeks for a signal. Compass says the data show effects within one day, and the company also describes durability through at least 6 months in responders. That is the kind of profile that can support a differentiated role in treatment, rather than leaving COMP360 as only a modest statistical improvement.

The VA trial and HMH collaboration target generalizability and delivery

Skeptics may question how well trial populations reflect real-world patients. The VA partnership helps address that concern. Compass is working with the U.S. Department of Veterans Affairs on a multi-site randomized controlled clinical trial in TRD, including patients with concurrent PTSD. That would broaden the evidence base in a more comorbid group and add operational credibility if successful.

The HMH collaboration matters for a different reason. HMH is working with Compass on the delivery model design for COMP360, if FDA-approved, to better understand real-world care-delivery challenges. If a new psilocybin treatment is going to scale outside a trial, issues like training, site workflow, and psychological support logistics need practical answers.

Regulatory momentum may reinforce the clinical story

There is also a process advantage. Compass says the FDA has granted rolling review and selected COMP360 for the Commissioner's National Priority Voucher program, which can shorten review by one to two months after filing. That does not guarantee approval, but it does suggest the agency is engaging with the package while it is still being built.

What could still prevent a rerating

The debate is no longer whether COMP360 has biological activity. The real debate is whether the market is still discounting timing, adoption, and execution enough to preserve upside.

Bulls are trading the calendar

The bull case is straightforward: the stock could rerate as the approval path compresses before the final verdict arrives. With final submission expected to be completed in Q4, investors are not paying only for past data; they are paying for a tighter path to review. Commercial launch-readiness is targeted for the end of 2026, with launch expected in the first half of 2027. If that timeline holds, optimism that still looks hesitant today could become the base case more quickly.

Bears will focus on adoption, not just approval

The bear case is less about efficacy and more about commercialization. Even with positive Phase 3 data, a new treatment can still stumble on workflow, training, reimbursement, and care-delivery logistics. That is exactly why the HMH collaboration exists: Compass is still working to inform the delivery model design for COMP360, if approved.

The VA partnership adds another tension point. A multi-site randomized controlled clinical trial in veterans, including those with concurrent PTSD, can strengthen credibility and generalizability. But it can also distract attention from the nearer TRD commercialization question. More evidence can be bullish for the science and still be neutral for the stock if it delays focus on launch execution.

What to watch next

Treat CMPS as a staged catalyst trade rather than a binary approval proxy. The setup improves if the NDA lands in the current Q4 window, if launch planning stays on schedule, and if the VA and HMH programs produce visible operating detail rather than just announcements.